Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases

Reducing blood culture contamination in the ED: impact of Kurin Lock® implementation.

Infection prevention in practice·2026

Language matters: Guidance for person-centred diabetes communication in Ireland.

Diabetic medicine : a journal of the British Diabetic Association·2026

The development and acceptability of an educational and training intervention for recruiters to neonatal trials: the TRAIN project.

BMC medical research methodology·2023

Low-density lipoprotein cholesterol in adolescents and young adults with type 1 diabetes: Data from the Australasian Diabetes Data Network registry.

Diabetic medicine : a journal of the British Diabetic Association·2023

Pyroglutamic acidosis caused by the combination of two common medicines prescribed in everyday practice.

Oxford medical case reports·2023

EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients.

ESMO open·2022

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Real-Time Single Molecule Imaging Reveals Pathway-Selective Action of Aducanumab on Amyloid-β Aggregation.

Nano letters·2026

B-Cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-Host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques.

Journal of medical virology·2026

Vogt-Koyanagi-Harada disease: Recent perspectives.

Indian journal of ophthalmology·2026

Tripartite motif protein 32 overexpression promotes inflammation and pyroptosis in INS-1 cells via the NF-κB/NLRP3 signaling pathway under high glucose conditions.

Endokrynologia Polska·2026

Related Experiment Videos

Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases

Related Concept Videos

Reducing blood culture contamination in the ED: impact of Kurin Lock® implementation.

Language matters: Guidance for person-centred diabetes communication in Ireland.

The development and acceptability of an educational and training intervention for recruiters to neonatal trials: the TRAIN project.

Low-density lipoprotein cholesterol in adolescents and young adults with type 1 diabetes: Data from the Australasian Diabetes Data Network registry.

Pyroglutamic acidosis caused by the combination of two common medicines prescribed in everyday practice.

EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Real-Time Single Molecule Imaging Reveals Pathway-Selective Action of Aducanumab on Amyloid-β Aggregation.

B-Cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-Host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques.

Vogt-Koyanagi-Harada disease: Recent perspectives.

Tripartite motif protein 32 overexpression promotes inflammation and pyroptosis in INS-1 cells via the NF-κB/NLRP3 signaling pathway under high glucose conditions.

Related Experiment Videos

Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases

Related Concept Videos

Related Articles